GoAI
Get started
Cyfuse Biomedical K.K. logo

Cyfuse Biomedical K.K.

4892.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥557

−¥8.00 · -1.42%

Aug 24, 3:30 PM JST

4892.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Shizuka Akieda
Listed since
Dec 1, 2022
Employees
23

Market position

Volume
8.7K
0.2× average
Average volume
42.77K
Average daily volume
Market cap
5.62B JPY
Beta
1.43
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.78B JPY
P/E (TTM)
-6.84×
P/B (TTM)
2.14×
P/S (TTM)
18.38×
EV / EBITDA
-3.51×
Earnings yield
-14.71%
Free cash flow yield
-11.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
47.49%
Operating margin
-253.17%
Net margin
-260.19%
Return on equity
-27.70%
Return on assets
-17.91%
Return on invested capital
-20.35%

Financial health

Debt / equity
0.47×
Current ratio
4.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends253%-438%-1128%-1819%Gross margin, FY2021: 80.23%Gross margin, FY2022: 59.80%Gross margin, FY2023: -0.62%Gross margin, FY2024: 2.87%Gross margin, FY2025: 33.94%Operating margin, FY2021: 9.96%Operating margin, FY2022: -113.52%Operating margin, FY2023: -1141.24%Operating margin, FY2024: -1645.91%Operating margin, FY2025: -358.52%Net margin, FY2021: 20.18%Net margin, FY2022: -126.57%Net margin, FY2023: -964.15%Net margin, FY2024: -1602.02%Net margin, FY2025: -330.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 80.23%. Gross margin FY2022 59.80%. Gross margin FY2023 -0.62%. Gross margin FY2024 2.87%. Gross margin FY2025 33.94%. Operating margin FY2021 9.96%. Operating margin FY2022 -113.52%. Operating margin FY2023 -1141.24%. Operating margin FY2024 -1645.91%. Operating margin FY2025 -358.52%. Net margin FY2021 20.18%. Net margin FY2022 -126.57%. Net margin FY2023 -964.15%. Net margin FY2024 -1602.02%. Net margin FY2025 -330.67%.

Income trends

Revenue

231M JPY+324.27%

Operating income

−828.18M JPY+7.58%

Net income

−763.84M JPY+12.43%
Income trends across reported periods868.68M JPY226.93M JPY−414.82M JPY−1.06B JPYRevenue, FY2021: 708.25M JPYRevenue, FY2022: 374.48M JPYRevenue, FY2023: 61.11M JPYRevenue, FY2024: 54.45M JPYRevenue, FY2025: 231M JPYOperating income, FY2021: 70.57M JPYOperating income, FY2022: −425.09M JPYOperating income, FY2023: −697.44M JPYOperating income, FY2024: −896.13M JPYOperating income, FY2025: −828.18M JPYNet income, FY2021: 142.91M JPYNet income, FY2022: −473.96M JPYNet income, FY2023: −589.21M JPYNet income, FY2024: −872.24M JPYNet income, FY2025: −763.84M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 708.25M JPY. Revenue FY2022 374.48M JPY. Revenue FY2023 61.11M JPY. Revenue FY2024 54.45M JPY. Revenue FY2025 231M JPY. Operating income FY2021 70.57M JPY. Operating income FY2022 −425.09M JPY. Operating income FY2023 −697.44M JPY. Operating income FY2024 −896.13M JPY. Operating income FY2025 −828.18M JPY. Net income FY2021 142.91M JPY. Net income FY2022 −473.96M JPY. Net income FY2023 −589.21M JPY. Net income FY2024 −872.24M JPY. Net income FY2025 −763.84M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue231M JPY54.45M JPY61.11M JPY374.48M JPY708.25M JPY
Cost of goods sold152.6M JPY52.88M JPY61.49M JPY150.54M JPY140.04M JPY
Gross profit78.4M JPY1.56M JPY−378K JPY223.93M JPY568.2M JPY
Research and development—469.56M JPY375.58M JPY303.69M JPY266.49M JPY
Selling, general, and administrative906.58M JPY428.13M JPY321.47M JPY345.33M JPY231.14M JPY
Operating expenses906.58M JPY897.69M JPY697.06M JPY649.02M JPY497.63M JPY
Interest income3.81M JPY480K JPY40K JPY41K JPY176K JPY
Interest expense14.28M JPY9.51M JPY9.77M JPY7.46M JPY5.24M JPY
Depreciation and amortization35.49M JPY36.02M JPY38.12M JPY54.29M JPY18.5M JPY
Operating income−828.18M JPY−896.13M JPY−697.44M JPY−425.09M JPY70.57M JPY
Net income−763.84M JPY−872.24M JPY−589.21M JPY−473.96M JPY142.91M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-20.9

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-10.74-17.26-23.79-30.31Q4 '24Q1 '25Q2 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -26.68, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -25.56, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -19.9, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 30, 2025: actual -28.96, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual -25.83, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -12.09, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -22.56, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -20.9, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates182.1M122.88M63.65M4.43MQ4 '24Q1 '25Q2 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual 8M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual 28M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual 24.21M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 30, 2025: actual 5.21M JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual 32.54M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 169M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 28M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 76M JPY, estimate —, surprise —, Comparison unavailable.

4892.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4892.T

research.disclaimer